AW
SUPN icon

Ankerstar Wealth’s Supernus Pharmaceuticals SUPN Stock Holding History

Ankerstar Wealth’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$512 Hold
11
– – ﹤0.01% 648
2026
Q1 		$569 Hold
11
– – ﹤0.01% 586
2025
Q4 		$547 Buy
+11
New +$535 ﹤0.01% 628

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Ankerstar Wealth's SUPN Position: Q2 2026 in Review

Ankerstar Wealth held its Supernus Pharmaceuticals (SUPN) position steady in Q2 2026 at 11 shares worth $512. The position accounts for ﹤0.01% of the portfolio, ranked #648.

Ankerstar Wealth first reported a position in SUPN in Q4 2025 and has held it in 3 quarters since. The position peaked at $569 in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Ankerstar Wealth held 11 shares of Supernus Pharmaceuticals worth $512 as of Q2 2026.
  • Ankerstar Wealth left its Supernus Pharmaceuticals share count unchanged in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Ankerstar Wealth's portfolio in Q2 2026, its #648 holding.
  • Ankerstar Wealth first reported a position in Supernus Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ankerstar Wealth's Supernus Pharmaceuticals position peaked at $569 in Q1 2026.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Ankerstar Wealth's 13F filing for Q2 2026, filed 13 Aug 2026.